Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals, and Alligator Bioscience AB announce that they have entered into a manufacturing services and supply agreement for the production of monoclonal antibody drug substance and drug product for preclinical studies and Phase 1-2 clinical trials.
Under the terms of the agreement, Cobra will be providing cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP supplies, as well as stability studies and qualified persons release for clinical trials.
Peter Coleman, CEO of Cobra Biologics said, “We believe that our comprehensive service offering, right from our excellent cell line development capability through to fill/finish at our recently acquired Matfors facility enabled us to win this important program with Alligator in a highly competitive market place.”
Alligator will be taking advantage of Cobra’s maxXpress service, which combines the UCOE protein expression technology with the experience and expertise of Cobra Biologics’ cell line development team and the Cello robotic clone selection system, to enable rapid clone selection and production of the monoclonal antibody.
Date: June 12, 2012
Source: Cobra Biologics
Filed Under: Drug Discovery
